Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety

Abstract Background Glucagon like peptide-1 receptor agonist (GLP-1RA) use in individuals with high atherosclerotic cardiovascular disease (ASCVD) risk reduces major adverse cardiovascular events (MACE). However, its clinical impact, in terms of numbers needed to treat (NNT), efficacy and safety pro...

Full description

Saved in:
Bibliographic Details
Main Authors: Ansel Shao Pin Tang, Jovan Teng Yuan Hsu, Sheena Kar Shuan Chong, Jingxuan Quek, Genevieve Shek, Farisah Sulaimi, Kai En Chan, Vickram Vijay Anand, Bryan Chong, Anurag Mehta, Sue-Anne Toh, Mark Muthiah, Georgios K. Dimitriadis, Carel W. le Roux, Mark Yan-Yee Chan, Mamas Andreas Mamas, Yip Han Chin, Nicholas W. S. Chew
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardiovascular Diabetology
Subjects:
GLP-1 receptor agonist
GLP-1RA
Myocardial infarction
Stroke
Cardiovascular mortality
Cardiovascular disease
Online Access:https://doi.org/10.1186/s12933-025-02840-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12933-025-02840-3

Similar Items